Clinical Trial Update: Study of MEK162 for Children With Low-Grade Gliomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of MEK162 for children with low-grade gliomas has completed, with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• MEK162 (binimetinib)

Snippet

Sponsor: Children's Hospital Los Angeles | Conditions: Low-Grade Gliomas, Malignant Neoplasms, Brain | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-10-07